What we do — in short.
We treat adults with overweight or obesity using Tirzepatide, combined with lifestyle coaching from a NOBCO-trained coach. A programme always begins with a thorough intake by our GP, and consists of a titration phase (20 weeks), a maintenance phase and a taper phase. Not every patient is eligible — and we discuss that openly, with you too if you'd like.
We do not replace regular care. We offer a programme alongside your consultations, not within them — for patients for whom this is, for whatever reason, not a fitting route within your own practice.
Full overview of the programme →
Which patients are suitable?
We follow the standard Dutch NHG/Healthcare Institute criteria for pharmacotherapy in obesity. For patients who fall outside those cut-offs we are also approachable — in practice, BMI is not always the best parameter, and we always assess the individual situation when in doubt.
— Suitable
- BMI ≥ 30, or
- BMI ≥ 27 with co-morbidity (OSA, hypertension, dyslipidaemia, prediabetes, MASLD)
- Patient is motivated for lifestyle change alongside medication
- Patient has no (or no longer) insurance coverage for treatment
- Or: BMI outside these limits but with a clear medical rationale — discussion welcome
— Not suitable
- Type 1 diabetes mellitus
- Personal or family history of MTC, MEN-2
- History of pancreatitis
- Pregnancy or pregnancy intent within 2 months
- Untreated severe psychiatric problems or active eating disorder
- Severe renal or hepatic insufficiency
BMI is a blunt measure. We recognise that some patients with a BMI below the threshold do clinically benefit from treatment — and conversely, that a BMI above the threshold doesn't automatically mean this programme is the right route. When in doubt, we're happy to take a look.
How do you refer?
Three routes — pick whatever suits your practice best:
— Option 01
Patient self-registers
The simplest route: refer the patient to our website. They complete the eligibility check and book their own intake.
Booking page →
— Option 02
Send a brief referral letter
Email a referral letter (free format is fine) with relevant history, medication and rationale to our referral address. We will then contact the patient within 2 working days.
verwijzers@lunaris-clinics.nl →
— Option 03
Phone consultation
For complex cases or co-morbidity questions we are happy to discuss in person. Call our general number and ask for the GP.
Contact & numbers →
What do you receive back?
Provided your patient gives explicit consent at intake, we send you a brief written progress report at three points — at 6, 12 and 18 months. Each report contains, at minimum:
- Weight, BMI, waist circumference (delta vs baseline)
- Blood pressure and heart rate
- Relevant lab values where taken (HbA1c, lipids, liver, kidney)
- Current Tirzepatide dose and side-effect profile
- Conclusion and advice — including any items that warrant attention in your consultations
For relevant incidents (e.g. suspected pancreatitis, serious adverse events, programme discontinuation for medical reasons) we contact you directly, regardless of the reporting schedule.
What we don't do.
Clarity here matters. Lunaris is not a replacement for regular care, and not for:
- Primary diabetes care — patients with type 1 or 2 diabetes are referred back to your practice or the internist.
- Bariatric surgery — no indication assessment, no pre- or post-op programmes.
- Eating-disorder treatment — for active eating disorders we refer to mental-health services.
- CPAP, biologic therapy or other specialist programmes — we can prescribe Tirzepatide as an addition, but the primary treatment stays with you or your specialist colleague.
- Psychiatric care — for active depression, suicidal ideation or psychosis we refer to mental-health services before any programme begins.
Safety & coordination.
Our GP is BIG-registered and the practice falls under the standard quality and complaints frameworks for Dutch general practice. We document according to the Wgbo and only share information with the patient's explicit written consent. We report adverse events directly to the Dutch Pharmacovigilance Centre Lareb in line with current guidelines.
We respect your role as the principal treating physician where that role belongs to you. In practice that means: when in doubt, or where there's overlap, we contact you before changing anything. No surprises.
Stay informed.
Leave your details below and we'll add you to our mailing list for healthcare professionals — no spam, only relevant updates on Tirzepatide programmes, progress-report formats and side-effect bulletins. You can unsubscribe at any time.